126 related articles for article (PubMed ID: 19536147)
1. The absence of BRAF, FGFR3, and PIK3CA mutations differentiates lentigo simplex from melanocytic nevus and solar lentigo.
Hafner C; Stoehr R; van Oers JM; Zwarthoff EC; Hofstaedter F; Klein C; Landthaler M; Hartmann A; Vogt T
J Invest Dermatol; 2009 Nov; 129(11):2730-5. PubMed ID: 19536147
[No Abstract] [Full Text] [Related]
2. FGFR3 and PIK3CA mutations are involved in the molecular pathogenesis of solar lentigo.
Hafner C; Stoehr R; van Oers JM; Zwarthoff EC; Hofstaedter F; Landthaler M; Hartmann A; Vogt T
Br J Dermatol; 2009 Mar; 160(3):546-51. PubMed ID: 19076977
[TBL] [Abstract][Full Text] [Related]
3. Phacomatosis pigmentokeratotica is caused by a postzygotic HRAS mutation in a multipotent progenitor cell.
Groesser L; Herschberger E; Sagrera A; Shwayder T; Flux K; Ehmann L; Wollenberg A; Torrelo A; Bagazgoitia L; Diaz-Ley B; Tinschert S; Oschlies I; Singer S; Mickler M; Toll A; Landthaler M; Real FX; Hafner C
J Invest Dermatol; 2013 Aug; 133(8):1998-2003. PubMed ID: 23337891
[TBL] [Abstract][Full Text] [Related]
4. FGFR3, PIK3CA and RAS mutations in benign lichenoid keratosis.
Groesser L; Herschberger E; Landthaler M; Hafner C
Br J Dermatol; 2012 Apr; 166(4):784-8. PubMed ID: 22188534
[TBL] [Abstract][Full Text] [Related]
5. Predictors of BRAF mutation in melanocytic nevi: analysis across regions with different UV radiation exposure.
Karram S; Novy M; Saroufim M; Loya A; Taraif S; Houreih MA; Rauscher B; Habib RH; Oberkanins C; Khalifeh I
Am J Dermatopathol; 2013 Jun; 35(4):412-8. PubMed ID: 23051629
[TBL] [Abstract][Full Text] [Related]
6. B-RAF and melanocytic neoplasia.
Gill M; Celebi JT
J Am Acad Dermatol; 2005 Jul; 53(1):108-14. PubMed ID: 15965430
[TBL] [Abstract][Full Text] [Related]
7. Genetic alterations in melanocytic tumors.
Takata M; Saida T
J Dermatol Sci; 2006 Jul; 43(1):1-10. PubMed ID: 16750612
[TBL] [Abstract][Full Text] [Related]
8. Extensive lentigo simplex, linear epidermolytic naevus and epidermolytic naevus comedonicus caused by a somatic mutation in KRT10.
Samuelov L; Sarig O; Gat A; Halachmi S; Shalev S; Sprecher E
Br J Dermatol; 2015 Jul; 173(1):293-6. PubMed ID: 25495838
[No Abstract] [Full Text] [Related]
9. BRAF mutations are common somatic events in melanocytic nevi.
Kumar R; Angelini S; Snellman E; Hemminki K
J Invest Dermatol; 2004 Feb; 122(2):342-8. PubMed ID: 15009715
[TBL] [Abstract][Full Text] [Related]
10. Lack of association between BRAF mutation and MAPK ERK activation in melanocytic nevi.
Uribe P; Andrade L; Gonzalez S
J Invest Dermatol; 2006 Jan; 126(1):161-6. PubMed ID: 16417232
[TBL] [Abstract][Full Text] [Related]
11. Chromosomal translocations as a mechanism of BRAF activation in two cases of large congenital melanocytic nevi.
Dessars B; De Raeve LE; El Housni H; Debouck CJ; Sidon PJ; Morandini R; Roseeuw D; Ghanem GE; Vassart G; Heimann P
J Invest Dermatol; 2007 Jun; 127(6):1468-70. PubMed ID: 17301836
[TBL] [Abstract][Full Text] [Related]
12. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S
Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847
[TBL] [Abstract][Full Text] [Related]
13. Melanocytic lesions, Spitz tumors, and Don Ferrante's logic.
Urso C
Am J Dermatopathol; 2007 Oct; 29(5):491-4. PubMed ID: 17890925
[No Abstract] [Full Text] [Related]
14. Atypical Phacomatosis Pigmentokeratotica as the Expression of a Mosaic RASopathy With the BRAF-Glu586Lys Mutation.
Ayala D; Ramón MD; Martín JM; Jordá E
Actas Dermosifiliogr; 2016 May; 107(4):344-6. PubMed ID: 26703821
[No Abstract] [Full Text] [Related]
15. RAS and RAF mutations in banal melanocytic aggregates contiguous with primary cutaneous melanoma: clues to melanomagenesis.
Dadzie OE; Yang S; Emley A; Keady M; Bhawan J; Mahalingam M
Br J Dermatol; 2009 Feb; 160(2):368-75. PubMed ID: 18945298
[TBL] [Abstract][Full Text] [Related]
16. Melanocytic nevi excised during B-Raf proto-oncogene (BRAF) inhibitor therapy: A study of 19 lesions from 10 patients.
Mochel MC; Hammond MR; Frederick DT; Alora-Palli MB; Piris A; Flaherty KT; Hoang MP
J Am Acad Dermatol; 2015 Sep; 73(3):491-9.e2. PubMed ID: 26190239
[TBL] [Abstract][Full Text] [Related]
17. Clonal BRAF mutations in melanocytic nevi and initiating role of BRAF in melanocytic neoplasia.
Yeh I; von Deimling A; Bastian BC
J Natl Cancer Inst; 2013 Jun; 105(12):917-9. PubMed ID: 23690527
[TBL] [Abstract][Full Text] [Related]
18. BRAF mutations are also associated with neurocutaneous melanocytosis and large/giant congenital melanocytic nevi.
Salgado CM; Basu D; Nikiforova M; Bauer BS; Johnson D; Rundell V; Grunwaldt LJ; Reyes-Múgica M
Pediatr Dev Pathol; 2015; 18(1):1-9. PubMed ID: 25490715
[TBL] [Abstract][Full Text] [Related]
19. Molecular pathogenesis of malignant melanoma: a different perspective from the studies of melanocytic nevus and acral melanoma.
Takata M; Murata H; Saida T
Pigment Cell Melanoma Res; 2010 Feb; 23(1):64-71. PubMed ID: 19788535
[TBL] [Abstract][Full Text] [Related]
20. Postzygotic BRAF p.Lys601Asn Mutation in Phacomatosis Pigmentokeratotica with Woolly Hair Nevus and Focal Cortical Dysplasia.
Kuentz P; Mignot C; St-Onge J; Duffourd Y; Bonniaud B; Faivre L; Rivière JB; Vabres P
J Invest Dermatol; 2016 May; 136(5):1060-1062. PubMed ID: 26829038
[No Abstract] [Full Text] [Related]
[Next] [New Search]
